On August 26, CSPC PHARMA rose 3.13% in regular trading, trading at HK$9.635/share, with turnover of HK$244 million.

On the news front, the company announced on August 25 that its self-developed recombinant respiratory syncytial virus vaccine SYS 6057 received FDA approval to conduct clinical trials in the United States, targeting prevention of RSV-caused lower respiratory tract disease in adults aged 60 and above. This marks the company's second recombinant protein vaccine to enter clinical stage. The product had previously received China's NMPA clinical trial approval in late July.

Additionally, following the company's interim results release showing revenue of RMB 18.59 billion (up 40.1% YoY) and attributable profit of RMB 6.09 billion (up 139.2% YoY), multiple international banks raised target prices. Goldman Sachs raised its target to HK$12.56, Morgan Stanley to HK$12, UBS to HK$11.80, Citi to HK$14, and Daiwa to HK$11.2, all maintaining buy ratings. The strong earnings, driven by approximately RMB 5.7 billion in licensing fee income, combined with the FDA milestone, continue to support the stock's recovery trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)